Pub. Date : 2018 Jan
PMID : 29187012
3 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Areas covered: Crizotinib, the first-in-class ALK/ROS1/MET inhibitor, was initially approved as second-line treatment of ALK-positive advanced NSCLC but after this, it was firmly established as the standard first-line therapy for advanced ALK-positive NSCLC. | Crizotinib | ROS proto-oncogene 1, receptor tyrosine kinase | Homo sapiens |
| 2 | Regarding ROS1 rearrangement, to date crizotinib is the only ALK-tyrosine kinase inhibitor receiving indication as treatment of ROS1 positive advanced NSCLC. | Crizotinib | ROS proto-oncogene 1, receptor tyrosine kinase | Homo sapiens |
| 3 | Regarding ROS1 rearrangement, to date crizotinib is the only ALK-tyrosine kinase inhibitor receiving indication as treatment of ROS1 positive advanced NSCLC. | Crizotinib | ROS proto-oncogene 1, receptor tyrosine kinase | Homo sapiens |